Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.40 |
| ▸ | CDK2 | P24941 | 8/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.40 |
| ▸ | CDK4 | P11802 | 5/20 | 0.38 |
| ▸ | CCND3 | P30281 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808191 | 1.00 | BRD4 (0.42) | BRD4KDRCCNA2CDK2CCNA1 | |
| SCHEMBL24309786 | 0.89 | DGAT2 (0.40) | BRD4SLC2A1 | |
| SCHEMBL26809807 | 0.88 | HTR6 (0.35) | BRD4 | |
| SCHEMBL24309701 | 0.87 | HTR6 (0.36) | BRD4SLC2A1 | |
| SCHEMBL29566991 | 0.87 | HTR1D (0.37) | BRD4 | |
| SCHEMBL26809817 | 0.87 | HTR1D (0.37) | BRD4 | |
| SCHEMBL24310014 | 0.86 | HTR1A (0.42) | BRD4 | |
| SCHEMBL29567227 | 0.86 | MAP4K1 (0.43) | BRD4 | |
| SCHEMBL24310343 | 0.86 | MAP4K1 (0.43) | BRD4 | |
| SCHEMBL29566394 | 0.86 | BRD4 (0.36) | BRD4CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BRD4 1716/4885KDR 4439/4885CCNA2 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.